

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
23 December 2021 (23.12.2021)



(10) International Publication Number  
**WO 2021/257943 A1**

(51) International Patent Classification:

A61B 18/14 (2006.01) A61K 39/395 (2006.01)  
A61K 35/17 (2015.01) A61K 45/00 (2006.01)  
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2021/038005

(22) International Filing Date:

18 June 2021 (18.06.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/041,493 19 June 2020 (19.06.2020) US

(71) Applicant: ONCOSEC MEDICAL INCORPORATED  
[US/US]; 24 North Main Street, Pennington, NJ 08534  
(US).

(72) Inventor: TWITTY, Christopher, G.; 3565 General  
Atomics Court, Suite 100, San Diego, CA 92121 (US).

(74) Agent: EKENA, Kirk et al.; Alston & Bird LLP, One South  
at The Plaza, 101 South Tryon Street, Suite 4000, Charlotte,  
NC 28280-4000 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS OF DETERMINING RESPONSIVENESS TO CANCER IMMUNOTHERAPY




FIG. 1A

(57) Abstract: Described are compositions comprising nucleic acids encoding CD3-half-BiTE, CXCL9, CTLA-4 scFv, and IL-12 for use in treating cancer. Methods of analyzing CXCR3 expression in a tumor to identify subjects likely to respond to the compositions are also described.



WO 2021/257943 A1